Christopher Boerner will take over the CEO role at Bristol Myers Squibb Company on 1 November when Giovanni Caforio retires. And as he has done for the last several BMS earnings calls as chief commercialization officer, Boerner spent the company’s first quarter 2023 call on 27 April discussing new launches that will drive revenue growth as current blockbusters lose exclusivity. In some high-profile products’ cases, he pleaded for patience as those assets establish their commercial footing.
Bristol announced long-time CEO Caforio’s retirement a day before the company reported $11.3bn in Q1 revenue, down 3% from the same period last year – a decline driven largely by a 37% drop in sales of its multiple myeloma drug Revlimid (lenalidomide) to $1.75bn due to increased generic competition globally
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?